ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
6.70
+0.44 (7.03%)
At close: Nov 18, 2026, 4:00 PM EST
6.70
0.00 (0.00%)
Pre-market: Nov 19, 2026, 8:37 AM EST
ImmunityBio Employees
As of December 31, 2025, ImmunityBio had 691 total employees, including 684 full-time and 7 part-time employees. The number of employees increased by 11 or 1.62% compared to the previous year. That makes ImmunityBio the 17,613th largest employer in the world and 2,418th in the United States.
Employees
691
Change (1Y)
11
Growth (1Y)
1.62%
Revenue / Employee
$264,214
Profits / Employee
-$1,605,867
Market Cap
7.13B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 691 | 11 | 1.62% | 684 | 7 |
| Sep 30, 2025 | 673 | 1 | 0.15% | 673 | 0 |
| Jun 30, 2025 | 685 | 63 | 10.13% | 685 | 0 |
| Mar 31, 2025 | 671 | 43 | 6.85% | 671 | 0 |
| Dec 31, 2024 | 680 | 52 | 8.28% | 680 | 0 |
| Sep 30, 2024 | 672 | 2 | 0.30% | 672 | 0 |
| Jun 30, 2024 | 622 | -61 | -8.93% | 622 | 0 |
| Mar 31, 2024 | 628 | -75 | -10.67% | 628 | 0 |
| Dec 31, 2023 | 628 | -97 | -13.38% | 628 | 0 |
| Sep 30, 2023 | 670 | -90 | -11.84% | 670 | 0 |
| Jun 30, 2023 | 683 | -57 | -7.70% | 683 | 0 |
| Mar 31, 2023 | 703 | 15 | 2.18% | 703 | 0 |
| Dec 31, 2022 | 725 | 138 | 23.51% | 725 | 0 |
| Sep 30, 2022 | 760 | 222 | 41.26% | 760 | 0 |
| Jun 30, 2022 | 740 | 229 | 44.81% | 740 | 0 |
| Mar 31, 2022 | 688 | 213 | 44.84% | 688 | 0 |
| Dec 31, 2021 | 587 | 138 | 30.73% | 587 | 0 |
| Sep 30, 2021 | 538 | 273 | 103.02% | 538 | 0 |
| Jun 30, 2021 | 511 | 246 | 92.83% | 511 | 0 |
| Mar 31, 2021 | 475 | 210 | 79.25% | 475 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Axsome Therapeutics | 1,390 |
| Arrowhead Pharmaceuticals | 1,062 |
| Twist Bioscience | 979 |
| Mirum Pharmaceuticals | 470 |
| Immunovant | 315 |
| Kodiak Sciences | 144 |
| ABIVAX Société Anonyme | 98 |
IBRX News
- 3 days ago - ImmunityBio Transcript: Jefferies Global Healthcare Conference - Transcripts
- 3 days ago - ImmunityBio Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 8 days ago - ImmunityBio announces findings from survey of military members with NMIBC - TheFly
- 8 days ago - New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care - Business Wire
- 8 days ago - ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 - Business Wire
- 9 days ago - ImmunityBio falls -18.3% - TheFly
- 9 days ago - ImmunityBio falls -22.6% - TheFly
- 10 days ago - ImmunityBio reports Q3 EPS (18c), consensus (8c) - TheFly